Key Concerns

Possible need for further radiotherapy: About 15-20% of patients may need to receive traditional radiotherapy in addition to TARGIT IORT if it is felt necessary after detailed examination of the tumour

Some uncertainty about the results: The safety of TARGIT IORT is well established but not all patients’ follow-up data beyond five years is available yet. It is possible that the risk of disease returning may be 1% higher than after traditional radiotherapy. However, there is a lower mortality (approximately 1%) with TARGIT IORT compared with standard radiotherapy treatments.